We are live on ! Find out more

Immunic

IMUX

Market cap $143M

10.47 USD

-0.76

6.77%

At close Updated Sep 15, 1:49 PM EDT

1 day

-6.77%

5 days

-17.69%

1 month

-34.68%

3 months

-25.27%

6 months

-9.74%

Year to date

79.59%

1 year

35.45%

5 years

-89.04%

10 years

-99.55%

About: Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.

Employees: 95

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 30%

Neutral 70%

Negative 0%

Immunic, Inc. (IMUX) Discusses R&D Advances and Future Directions in Relapsing Multiple Sclerosis Transcript

Immunic, Inc. (IMUX) Discusses R&D Advances and Future Directions in Relapsing Multiple Sclerosis Transcript

Immunic, Inc. (IMUX) Discusses R&D Advances and Future Directions in Relapsing Multiple Sclerosis Transcript

Proactive Investors

Immunic to host virtual relapsing MS R&D Day on September 9

Immunic Inc (NASDAQ:IMUX, FRA:10VA) announced that it will host a virtual research and development day focused on relapsing multiple sclerosis on September 9, as the biotechnology company prepares for topline results from its Phase 3 ENSURE trials expected by the end of 2026. The event will feature Immunic management, including CEO Erik Lundgren, chief medical officer Michael Panzara, chief scientific officer Hella Kohlhof and president and chief operating officer Jason Tardio.

Immunic to host virtual relapsing MS R&D Day on September 9

Immunic to Host Virtual Relapsing Multiple Sclerosis R&D Day on September 9, 2026

NEW YORK, Sept. 2, 2026 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced that it will host a virtual research and development (R&D) day focused on relapsing multiple sclerosis (MS) on Wednesday, September 9, 2026, at 11:00 am ET.

Immunic to Host Virtual Relapsing Multiple Sclerosis R&D Day on September 9, 2026

Immunic Appoints Chitrang Davé as Chief Data and Digital Officer

– New C-Suite Role and Appointment Underscore Commitment to Building a Strong, Commercial-Ready Data Ecosystem, in Preparation for Potential NDA Submission and Commercialization – NEW YORK, Sept. 1, 2026 /PRNewswire/ -- Immunic , Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced the appointment of Chitrang Davé as Chief Data and Digital Officer (CDDO), effective today.

Immunic Appoints Chitrang Davé as Chief Data and Digital Officer

Immunic: Potent Under-The-Radar MS Lineup Set For A Rerating

Immunic is advancing vidofludimus calcium (IMU-838) in late-stage trials for both relapsing and progressive multiple sclerosis. MS represents a substantial market, with existing therapies projected to reach ~$22 billion in 2026 revenues. IMU-838's oral administration and differentiated mechanism of action position it as a potential major player in the MS market.

Immunic: Potent Under-The-Radar MS Lineup Set For A Rerating

Zacks Investment Research

Can Immunic (IMUX) Climb 163.03% to Reach the Level Wall Street Analysts Expect?

The mean of analysts' price targets for Immunic (IMUX) points to a 163% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Can Immunic (IMUX) Climb 163.03% to Reach the Level Wall Street Analysts Expect?

Proactive Investors

Immunic advances MS drug toward key Phase 3 data, expects results by year-end

Immunic Inc (NASDAQ:IMUX, FRA:10VA) is preparing for a series of clinical and corporate milestones as it advances its lead drug candidate vidofludimus calcium through late-stage development in multiple sclerosis, while expanding its leadership team ahead of potential regulatory filings and commercialization. The biotechnology company reported second-quarter results on Tuesday and said its Phase 3 ENSURE-1 and ENSURE-2 trials evaluating vidofludimus calcium in relapsing multiple sclerosis remain on track to deliver top-line data by the end of 2026.

Immunic advances MS drug toward key Phase 3 data, expects results by year-end

Immunic, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update

– Leadership Team Expanded with Key Executive Appointments, Including Chief Executive Officer, Chief Medical Officer and Chair of the Board of Directors, to Support Clinical Development, as well as NDA and Commercial Readiness – – Pivotal Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis on Track, with Top-Line Data Expected by End of 2026 – – Continued Preparations for Phase 3 Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis, with Initiation Planned Later This Year – NEW YORK, Aug. 11, 2026 /PRNewswire/ -- Immunic , Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today reported financial results for the second quarter ended June 30, 2026, and provided a corporate update. "During the second quarter, we continued to execute across our late-stage development priorities as we advance toward what we believe will be a transformational period for Immunic," said Erik Lundgren, Chief Executive Officer of Immunic.

Immunic, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Immunic Appoints Elena Ridloff to Board of Directors

– Appointment Strengthens Board with Financial, Capital Markets and Commercial Leadership Expertise as the Company Approaches Pivotal Phase 3 ENSURE Readout in Relapsing Multiple Sclerosis as well as Potential Regulatory Filings and Commercialization – NEW YORK, Aug. 10, 2026 /PRNewswire/ -- Immunic , Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced the appointment of Elena Ridloff, CFA to its Board of Directors, effective August 6, 2026. Ms. Ridloff brings more than two decades of experience driving financial strategy, corporate growth, and capital markets execution across the biopharmaceutical industry.

Immunic Appoints Elena Ridloff to Board of Directors

Immunic to Participate in Investor Conferences in July

NEW YORK, July 9, 2026 /PRNewswire/ -- Immunic , Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced participation in the following investor conferences in July: July 14-15: Leerink Partners Therapeutics Forum. Erik Lundgren, Chief Executive Officer, Jason Tardio, President and Chief Operating Officer, Michael A.

Immunic to Participate in Investor Conferences in July

See News Rankings

Price charts implemented using Lightweight Charts™